FMP
Exscientia plc
EXAI
NASDAQ
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
4.44 USD
0.12 (2.7%)
About
ceo
Dr. David Hallett Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.exscientia.ai
exchange
NASDAQ
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
CIK
0001865408
ISIN
US30223G1022
CUSIP
30223G102
Address
The SchrOedinger Building
Phone
44 18 6581 8941
Country
GB
Employee
483
IPO Date
Oct 1, 2021
Summary
CIK
0001865408
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
30223G102
ISIN
US30223G1022
Country
GB
Price
4.44
Beta
0.78
Volume Avg.
746.29k
Market Cap
558.12M
Shares
-
52-Week
4.17-9.12
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.02
P/B
-
Website
https://www.exscientia.ai
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EXAI News
It looks like there's no news available.
